SHANGHAI, March 19, 2021 /PRNewswire/ — Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, today announced that it will report financial results for the full year ended December 31, 2020 and provide a business update on March 22, 2021.
Conference Call Information
A live conference call will be hosted on March 22, 2021 at 9:00 a.m. China Standard Time (March 21, 2021 at 9:00 p.m. Eastern Time). Details are as follows:
Conference ID 7234522#
|
Australia |
+61 2 8223 9906 |
|
Mainland China |
4008 428 338 |
|
Hong Kong |
+852 2112 1888 |
|
India |
000 800 440 2261 |
|
Indonesia |
001 803 440 117 |
|
Japan |
+81 3 5767 9336 |
|
Korea |
+82 2 3483 1262 |
|
Malaysia |
+60 3 6207 4051 |
|
Singapore |
+65 6622 1172 |
|
Taiwan |
+886 2 2162 6306 |
|
Thailand |
+66 2 0321 630 |
|
UK |
+44 0203 024 5279 |
|
Denmark |
+45 3 272 7715 |
|
France |
+33 1 7091 8635 |
|
Germany |
+49 69 8092 1475 |
|
Italy |
+39 02 3041 0447 |
|
Netherlands |
+31 20 794 7985 |
|
Sweden |
+46 8 5051 3551 |
|
Switzerland |
+41 43 456 9554 |
|
US |
+1 212 444 0378 |
A replay will be available shortly after the call and can be accessed by visiting the Company’s website at https://www.everestmedicines.com.
About Everest Medicines
Everest Medicines is a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record of high-quality clinical development, regulatory affairs, CMC, business development and operations both in China and with leading global pharmaceutical companies. Everest Medicines has built a portfolio of eight potentially global first-in-class or best-in-class molecules, many of which are in late-stage clinical development. The Company’s therapeutic areas of interest include oncology, autoimmune disorders, cardio-renal diseases and infectious diseases. For more information, please visit its website at www.everestmedicines.com.